Bambusa Therapeutics, Inc. (Nasdaq: BBTX) (Bambusa), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, has announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of US$16 per share. The gross proceeds to Bambusa from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bambusa, are expected to be US$168.9 million. In addition, Bambusa has granted the underwriters a 30-day option to purchase up to an additional 1,583,333 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Bambusa.
Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Rachel Moore and Sam Berry.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
